Preclinical Study Presented At AACR Annual Meeting Shows Broad Anti-Cancer Potential Of Peregrine’s Anti-PS Vascular Targeting Antibodies

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) announced that a preclinical study being presented by an independent team of investigators at the 2008 Annual Meeting of the American Association for Cancer Research (AACR) further illustrates the broad anti-tumor potential of its anti-phosphatidylserine (anti-PS) vascular targeting antibodies. The study by Dr. Yayun Liang, Dr.

More: continued here

Filed under: Biology on April 17th, 2008